B1791089: An Open-Label, Multicenter Study To Evaluate The Pharmacokinetics of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Who Are Candidates For Acid Suppression Therapy
Study of Drug in Patients 1-16 Years of Age with Gastroesophageal Reflux Disease (GERD)
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAR4382
U.S. Govt. ID: NCT02401035
Contact: Joseph Picoraro, MD: 212-305-5903 / jp3386@cumc.columbia.edu
Additional Study Information: The purpose of this study is to characterize the pharmacokinetics (PK) and safety of intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid suppression therapy.
This study is closed
Joseph Picoraro, MD
Do You Qualify?
Is your child between 1 and 16 years of age? Yes No
Is your child expected to be hospitalized due to illness for at least 7 days? Yes No
s your child a candidate for acid suppression therapy (ie, GERD, suspected GERD, symptomatic GERD, endoscopically proven GERD)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Joseph Picoraro, MD